Development of research assets in collaboration with external research entities
CombiGene conducts no research under its own management, but sources development assets via collaboration with an external research network. The advantages with this type of collaboration are apparent for both parties. CombiGene is able to gain access to leading research from the academic world without having to incur costs for resource-intensive research. In turn, the academic researchers gain access to CombiGene’s considerable expertise in pharmaceuticals development and project management, and financial resources to enable preclinical and clinical development.
Leading-edge expertise and experience
CombiGene has a team of very knowledgeable and experienced professionals, as well as solid, longstanding experience from the international pharma industry and the biotech arena, together with a thorough knowledge of all aspects of gene therapy. This combination of experience and leading-edge expertise allows CombiGene, together with a network of selected external partners who complement CombiGene’s internal expertise, to conduct ground-breaking gene-therapeutic development very effectively.
Methodology development and preclinical studies in collaboration with leading international players
To use the company’s resources as effectively as possible CombiGene seeks to develop manufacturing methods and conduct preclinical/clinical studies in collaboration with leading external partners in the respective areas. In this way CombiGene is able to choose the most suitable partner and thereby drive the projects as effectively and successfully as possible.
Commercialization in collaboration with leading pharmaceutical companies
Under its own management, CombiGene’s ambition is to take its candidate drugs through preclinical development up to initial studies in humans. Candidate drugs for commonly occurring illnesses will be commercialized through strategic partnerships and CombiGene is making extensive partnering efforts in order to build long-term relations with interesting international pharmaceutical companies. For drugs targeting niched patient populations CombiGene may establish its own sales channels.
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.
The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 firstname.lastname@example.org.